- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Mania AND Bipolar Disorder.
Displaying page 3 of 5.
EudraCT Number: 2015-000606-20 | Sponsor Protocol Number: A1281132 | Start Date*: 2015-04-03 |
Sponsor Name:Pfizer, Inc. | ||
Full Title: Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Dis... | ||
Medical condition: Bipolar Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2004-001308-11 | Sponsor Protocol Number: F1D-XM-HGLW | Start Date*: 2004-08-19 | |||||||||||
Sponsor Name:Lilly.S.A. | |||||||||||||
Full Title: Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies | |||||||||||||
Medical condition: to compare the efficacy in the prevention of relapse to manic, depressive, or mixed episodes in two groups of bipolar I patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000803-25 | Sponsor Protocol Number: RGH-MD-25 | Start Date*: 2019-10-02 | ||||||||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION... | ||||||||||||||||||
Medical condition: Bipolar I disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004789-14 | Sponsor Protocol Number: D1050308 | Start Date*: 2012-07-04 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label, Flexible-Dose Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects with Bipolar I Disorder | |||||||||||||
Medical condition: bipolar disorder I | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed) HR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016041-25 | Sponsor Protocol Number: RGH-MD-36 | Start Date*: 2010-05-12 | |||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||
Full Title: A Long-Term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder | |||||||||||||
Medical condition: Bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018671-20 | Sponsor Protocol Number: P06384 | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Forest Research Institute Inc., a wholly owned subsidiary of Forest Laboratories, LLC | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phas... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006426-26 | Sponsor Protocol Number: D1443L00009 | Start Date*: 2007-01-17 |
Sponsor Name:AstraZeneca AB | ||
Full Title: FAST – A randomised, open-label, parallel, multicentre Phase IIIb Study to evaluate the Efficacy and Safety of Quetiapine IR titrared over 4 Days in Patients with Acute Psychosis (Rapid versus Conv... | ||
Medical condition: Patients requiring treatment, as judged by the Investigator, for an acute episode of schizophrenia, schizoaffective disorder, psychosis NOS or bipolar mania (according to DSM-IV criteria). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002133-13 | Sponsor Protocol Number: PRA/BIA-2093-204 | Start Date*: 2005-10-21 |
Sponsor Name:BIAL - Portela & Ca, S.A. | ||
Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, FIXED MULTIPLE DOSE, RANDOMIZED, PLACEBO-CONTROLLED, MULTICE... | ||
Medical condition: Patients with acute manic episodes fulfilling DSM-IV criteria for Bipolar I Disorder. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002134-35 | Sponsor Protocol Number: PRA+SCO/BIA-2093-205 | Start Date*: 2005-09-27 |
Sponsor Name:Bial - Portela & Cª, S.A. | ||
Full Title: EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER | ||
Medical condition: recurrence prevention of bipolar I disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) ES (Completed) CZ (Completed) DE (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004334-42 | Sponsor Protocol Number: 31-08-252 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder | |||||||||||||
Medical condition: Bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000202-49 | Sponsor Protocol Number: CN138-134 | Start Date*: 2005-02-22 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy Revised... | ||
Medical condition: Bipolar disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) HU (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001935-30 | Sponsor Protocol Number: ELND005-BPD201 | Start Date*: 2012-11-27 |
Sponsor Name:Elan Pharma International Ltd | ||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder | ||
Medical condition: Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) ES (Completed) LT (Prematurely Ended) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001472-12 | Sponsor Protocol Number: A7501009 Amendment 1 | Start Date*: 2006-04-12 | |||||||||||
Sponsor Name:N V Organon | |||||||||||||
Full Title: A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing Trial A7501008 and Continuing Lithium or Valproic Acid/Divalp... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000589-11 | Sponsor Protocol Number: F1D-MC-HGKR | Start Date*: 2004-08-10 |
Sponsor Name:ELI LILLY and COMPANY | ||
Full Title: Protocol F1D-MC-HGKR. Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder | ||
Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002131-27 | Sponsor Protocol Number: SCO/BIA-2093-203 | Start Date*: 2005-09-27 |
Sponsor Name:BIAL - Portela & Ca, S.A. | ||
Full Title: Efficacy and safety of eslicarbazepine acetate (BIA 2-093) in acute manic episodes associated with bipolar I disorder in a double-blind, randomised, dose-titration, placebo-controlled, multicenter ... | ||
Medical condition: Patients with acute manic episode fulfilling DSM-IV criteria for Bipolar I Disorder (i.e., 296.0, 296.4 or 296.6) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) CZ (Completed) DE (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000757-13 | Sponsor Protocol Number: RGH-MD-54 | Start Date*: 2016-06-07 | |||||||||||
Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo... | |||||||||||||
Medical condition: Bipolar I Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002213-19 | Sponsor Protocol Number: ELICE-BD-O1 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:University of British Columbia | |||||||||||||
Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa... | |||||||||||||
Medical condition: Euthymic Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003781-14 | Sponsor Protocol Number: RISBIM3003 | Start Date*: 2004-12-02 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder,... | ||
Medical condition: BIPOLAR MANIA | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000915-25 | Sponsor Protocol Number: D1447C00144 | Start Date*: 2005-04-22 | |||||||||||
Sponsor Name:AstraZeneca R&D Sodertalje | |||||||||||||
Full Title: Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenanc... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002870-30 | Sponsor Protocol Number: 31-08-250 | Start Date*: 2013-01-13 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma... | |||||||||||||
Medical condition: Bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
